Pyridazin-3-formamide compounds as tyk2 inhibitors
HK40097123BActive Publication Date: 2026-09-18GUANGZHOU FERMION TECHNOLOGY CO LTD
View PDF 0 Cites -1 Cited by
Patent Information
- Application Number
- HK42024085332
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2022-06-07
- Filing Date
- 2024-01-12
- Publication Date
- 2026-09-18
- Estimated Expiration
- 2043-06-05
AI Technical Summary
Technical Problem
Existing small-molecule JAK inhibitors have low selectivity for JAK family kinases and are difficult to effectively inhibit TYK2 kinase, leading to adverse reactions when treating related diseases.
Method used
To develop a pyridazine-3-carboxamide compound that selectively inhibits TYK2 by binding to the JH2 domain of TYK2, for the treatment of TYK2-mediated diseases.
Benefits of technology
It provides excellent selective inhibitory activity against TYK2, reduces the impact on other JAK family kinases, lowers the risk of adverse reactions, and improves the efficacy of treating TYK2-mediated diseases.
✦ Generated by Eureka AI based on patent content.
Abstract
The present invention provides pyridazine-3-carboxamide compounds of general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof. The present invention also provides pharmaceutical compositions comprising said compounds, processes for their preparation and their use in the treatment or prevention of TYK2 kinase-mediated diseases.
Need to check novelty before this filing date? Find Prior Art